Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis

American Journal of Respiratory and Critical Care Medicine

Volumn 180, Issue 3, 2009, Pages 273-280

  Dorman, Susan E ^a   Johnson, John L ^b,d   Goldberg, Stefan ^c   Muzanye, Grace ^d   Padayatchi, Nesri ^e   Bozeman, Lorna ^c   Heilig, Charles M ^c   Bernardo, John ^f,y   Choudhri, Shurjeel ^g   Grosset, Jacques H ^a   Guy, Elizabeth ^h,n   Guyadeen, Priya ⁱ   Leus, Maria Corazon ^j,u   Maltas, Gina ^a   Menzies, Dick ^k,ag   Nuermberger, Eric L ^a   Villarino, Margarita ^c   Vernon, Andrew ^c   Chaisson, Richard E ^a   Mugerwa, Roy D ^d   Mayanja Kizza, Harriet ^d   Gitta, Phineas ^d   Okwera, Alphonse ^d   Lamunu, Dorcas ^d   Nsubuga, Pheona ^d   Joloba, Moses ^d   Morgan, Karen ^d   Mulumba, Yusuf ^d   Nakibali, Joseph G ^d   Kimera, James ^d   Ssaku, Elias ^d   El Sadr, Wafaa ^e,ac   Bamber, Sheila ^e   Christop Chinappa, Surie T ^e   Hirsch Moverman, Yael ^e   Naidoo, Vikesh ^e   Mnguni, Nelisiwe ^e   Mthethwa, Thokozani ^e   Gumede, Zevile ^e   Ganas, Kaloshnee ^e   Conde, Marcus B ^l   Efron, Anne ^l   Loredo, Carla ^l   Marsico, Anna Grazia ^l   Vieira, Gisele Betzler De Oliveira ^l   Weis, Stephen ^m   King, Barbara ^m   Turk, Le ^m   Stevenson, Gloria ^m   Helal, Joseph ^m   Shafer, Norma ^m   Dunbar, Denise ^m   Hamill, Richard ⁿ   Scott, Terry ⁿ   Nickson, Ruby ⁿ   Goodrich, Kathleen ⁿ   Cayla, Joan A ^o   Miró, Jose M ^o   Sanchez, Francesca ^o   Moreno, Antonio ^o   Martinez, José A ^o   Sambeat, M Antònia ^o   López Colomés, Jose L ^o   De Souza, M Luiza ^o   Jiménez, M Angeles ^o   Milà, Celia ^o   Lacasa, Xavier Martínez ^o   Coll, Pere ^o   Cuchi, Eva ^o   Gonzalez, Julian ^o   Martin, Nuria ^o   Salvado, Margarita ^o   Weiner, Marc H ^p,w   Wing, Richard ^p   Wing, Diane ^p   Uribe, Juan ^p   Engle, Melissa ^p,w   Calderin, Agustin ^p   Catanzaro, Antonino ^q   Moser, Kathleen S ^q   Tracy, Mark J ^q   Francisco, Vivien Peach ^q   Davis, Judy ^q   Reed, Sharon ^q   Peter, Christopher R ^q   Jones, Brenda E ^r   Rayos, Ermelinda ^r   Brown, Maria ^r   Oamar, Bonnie P ^r   Sum, Samuel ^r   Reves, Randall ^s   Burman, William ^s   Tapy, Jan ^s   Belknap, Robert ^s   Sanchez, Grace ^s   Hildred, Ginger ^s   Pachucki, Constance ^t   Marantz, Susan ^t   Lee, Anna ^t   Samuel, Mary Poly ^t   Kubba, Sue ^t   Mangura, Bonita T ^u   Reichman, Lee B ^u   Owens, Marilyn ^u   Napolitano, Eileen ^u   Burday, Michelle ^u   Sickles, Debra ^u   Ray, Susan M ^v   Holland, David P ^v   Dixon, Deirdre ^v   Mohamed, Omar ^v   Folami, Kanoa ^v   Bush, Jane ^v   Duran, Paula ^w   Sadkowski, Lee C ^w   Dorman, Susan ^a   Fisher, James ^a   Hooper, Nancy ^a,t   Kepron, Wayne ^x   Roth, Marian ^x   Hoban, Daryl ^x   Saukkonen, Jussi ^y   Horsburgh Jr , C Robert ^y   Murphy, Claire ^y   Brett Curran, Denise ^y   Westerling, Judith ^y   Schluger, Neil W ^z   Burzynski, Joseph ^z   Lozano, Vilma ^z   Wolk, Magda ^z   Ebrahimzadeh, Adeleh ^z   Hamilton, Carol Dukes ^aa   Stout, Jason ^aa   Mosher, Ann ^aa   Hecker, Emily ^aa   Bargothi, Shadia ^aa   Bhattacharya, Mondira ^ab   Lippold, Susan ^ab   Clapp, William ^ab   Fabre, Julie ^ab   Narwocki, John ^ab   Klein, Mary ^ac   Tankoano, Yombo ^ac   Badshah, Cyrus ^ac   Schichi, John ^ac   Al Nasir, Mussa ^ac   Razeq, Jafar H ^ac   Narita, Masa ^ad   Schwartz, Debra ^ad   Pass, Jean ^ad   Nahid, Payam ^ae   Hopewell, Philip ^ae   Merri field, Cindy ^ae   Rudoy, Irina ^ae   Israel, Jill ^ae   Babst, Anna ^ae   Sterling, Timothy R ^af   Kerrigan, Amy ^af   Smith, Teresa ^af   Gordin, Fred M ^t   Benator, Debra ^t   Conwell, Donna Sepulveda ^t   Schwartzman, Kevin ^ag   Greenaway, Christina ^ag   Pelletier, Marthe ^ag   Valiquette, Chantal ^ag   Plaisir, Paul ^ag   Thibert, Louise ^ag   more..

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e UNIVERSITY OF KWAZULU NATAL   (South Africa)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g BAYER CORPORATION   (United States)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

ⁱ WESTAT   (United States)

^j UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^k MCGILL UNIVERSITY   (Canada)

^l Brazil Johns Hopkins University Research Collaboration   (Brazil)

^m UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

ⁿ Michael Debakey Veterans Affairs Medical Center   (United States)

^o UNIVERSITY OF BARCELONA   (Spain)

^p South Texas Audie Murphy VA Hospital Research Collaboration   (United States)

^q UCSD MEDICAL CENTER   (United States)

^r UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^s DENVER PUBLIC HEALTH   (United States)

^t VETERANS AFFAIRS MEDICAL CENTER   (United States)

^u RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^v EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^w SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^x UNIVERSITY OF MANITOBA   (Canada)

^y BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^z University of Manitoba ^*  (United States)

^aa DUKE UNIVERSITY   (United States)

^ab JESSE BROWN VA MEDICAL CENTER   (United States)

^ac HARLEM HOSPITAL CENTER   (United States)

^ad Pub Health Seattle and King County   (United States)

^ae UNIVERSITY OF CALIFORNIA   (United States)

^af VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^ag MCGILL UNIVERSITY   (Canada)

more..

Author keywords

Antitubercular agents; Mycobacterium infections; Tuberculosis

Indexed keywords

ANTIINFECTIVE AGENT; ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; PLACEBO; PYRAZINAMIDE; RIFAMPICIN;

ANTIMICROBIAL ACTIVITY; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG POTENCY; DRUG SAFETY; HUMAN; IN VITRO STUDY; INTENSIVE CARE; JOINT DISCOMFORT; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MOUSE; MULTIVARIATE ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SPUTUM CULTURE; SPUTUM SMEAR; THORAX RADIOGRAPHY; TREATMENT OUTCOME; VOMITING;

EID: 67749086328     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200901-0078OC     Document Type: Article

References (39)

1. Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, Chaisson RE, Bishai WR, Grosset JH. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004;169:421-426.
2. Nuermberger EL, Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, O'Brien RJ, Vernon AA, Chaisson RE, Bishai WR, Grosset JH. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 2004;170:1131-1134.
3. Sullivan JT, Woodruff M, Lettieri J, Agarwal V, Krol GJ, Leese PT, Watson S, Heller AH. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob Agents Chemother 1999;43:2793-2797.
4. Peloquin CA, Hadad DJ, Molino LP, Palaci M, Boom WH, Dietze R, Johnson JL. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2008;52:852-857.
5. Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998;42:2066-2069.
6. Miyazaki E, Miyazaki M, Chen JM, Chaisson RE, Bishai WR. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother 1999;43:85-89.
7. Gosling RD, Uiso LO, Sam NE, Bongard E, Kanduma EG, Nyindo M, Morris RW, Gillespie SH. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2003;168:1342-1345.
8. Hu Y, Coates AR, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003;47:653-657.
9. Johnson JL, Hadad DJ, Boom WH, Daley CL, Peloquin CA, Eisenach KD, Jankus DD, Debanne SM, Charlebois ED, Maciel E, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006;10:605-612.
10. Ball P, Stahlmann R, Kubin R, Choudhri S, Owens R. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 2004;26:940-950.
11. Gavin JR III, Kubin R, Choudhri S, Kubitza D, Himmel H, Gross R, Meyer JM. Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies. Drug Saf 2004;27:671-686.
12. Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, Stumpo C, Dresser L, Low DE, Mamdani MM. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006;354:1352-1361.
13. Mitchison DA. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis 1993;147:1062-1063. (letter).
14. Dorman S, Johnson J, Padayatchi N, Goldberg S, Bozeman L, Chaisson R. Moxifloxacin vs isoniazid in the first 2 months of treatment for pulmonary tuberculosis. Presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL; Sept 17-20, 2007. Abstract L-736-B.
15. Dorman S, Johnson J, Padayatchi N, Goldberg S, Bozeman L, Chaisson R. Moxifloxacin vs isoniazid in the first 2 months of treatment for pulmonary tuberculosis. Presented at the 38th Union World Conference on Lung Health; Cape Town, South Africa; Nov 8-12, 2007.
16. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkine SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, et al., American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-662.
17. Kent PT, Kubica GP. Public health mycobacteriology: a guide for the level III laboratory. Atlanta, GA: U.S. Department of Health and Human Services; 1985.
18. East Afican/British Medical Research Councils. Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1972;1:1079-1085.
19. East Afican/British Medical Research Councils. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1974;2:1100-1106.
20. East Afican/British Medical Research Councils. Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis: first report: Third East African/British Medical Research Councils study. Am Rev Respir Dis 1978;118:39-48.
21. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis. First report. Am Rev Respir Dis 1978;118:219-228.
22. Hong Kong Chest Service/British Medical Research Council. Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Lancet 1981;1:171-174.
23. Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, Choudhri S, Daley CL, Munsiff SS, Zhao Z, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006;174:331-338.
24. Rustomjee R, Lienhardt C, Kanyok T. Gatifloxacin for TB (OFLOTUB) study team. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008;12:128-138.
25. Conde MB, Efron A, Loredo C, De Souza GR, Gracxa NP, Cezar MC, Ram M, Chaudhary MA, Bishai WR, Kritski AL, Chaisson RE. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009;53:1314-1319.
26. Aber VR, Nunn AJ. Factors affecting relapse following short-course chemotherapy. Bull Int Union Tuberc 1978;53:260-267.
27. Tripathy SP. Relapse in tuberculosis. Indian J Tuberc 1981;28:45-57.
28. Lounis N, Bentoucha A, Truffot-Pernot C, Ji B, O'Brien RJ, Vernon A, Roscigno G, Grosset J. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 2001;45:3482-3486.
29. Grosset J, Ji B. Experimental chemotherapy of mycobacterial diseases. In: Gangadharam PRJ, Jenkins PA, editors. Mycobacteria, Vol. II: Chemotherapy. New York: Chapman & Hall; 1998: pp. 51-97.
30. Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset JH, Nuermberger EL. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 2007;4:e344.
31. Nuermberger E, Tyagi S, Tasneen R, Williams KN, Almeida D, Rosenthal I, Grosset JH. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 2008;524:1522-1524.
32. Nuermberger E, Yoshimatsu T, Tyagi S, Bishai WR, Grosset J. Assessment of moxifloxacin activity at clinically relevant dosages in the mouse model of tuberculosis [abstract]. Am J Respir Crit Care Med 2003;169:A433.
33. Lubasch A, Keller I, Borner K, Koeppe P, Lode H. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000;44:2600-2603.
34. Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharath S, Balasubramanian V. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother 2007;51:576-582.
35. Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis 1989;140:1189-1193.
36. Lalande V, Truffot-Pernot C, Paccaly-Moulin A, Grosset J, Ji B. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 1993;37:407-413.
37. Williams KN, Stover CK, Zhu T, Tasneen R, Tyagi S, Grosset JH, Nuermberger E. Promising anti-tuberculosis activity of the oxazolidinone PNU-100480 relative to linezolid in the murine model. Antimicrob Agents Chemother 2009;53:1314-1319.
38. Rosenthal IM, Williams K, Tyagi S, Vernon AA, Peloquin CA, Bishai WR, Grosset JH, Nuermberger EL. Weekly moxifloxacin and rifapentine is more active than the Denver regimen in murine tuberculosis. Am J Respir Crit Care Med 2005;172:1457-1462.
39. Kubendiran G, Paramasivan CN, Sulochana S, Mitchison DA. Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis. J Chemother 2006;18:617-623.